Sanofi wins FDA TB nod; UCB brings on Daiichi to market Vimpat in Japan;

> Sanofi ($SNY) has won FDA approval for Priftin tablets to treat latent tuberculosis infection. Release (PDF)

> Daiichi Sankyo has teamed up with UCB to commercialize epilepsy treatment Vimpat in Japan. Report

> Ranbaxy and Epirus have launched a biosimilar of Johnson & Johnson's ($JNJ) Remicade in India. More

> The EU has greenlighted Astellas' Xtandi for prechemo prostate cancer. Report

> Otsuka says new pickup Avanir's ($AVNR) sales and marketing capabilities can help it create a global CNS company. Release

And Finally... GlaxoSmithKline ($GSK) has named the winners for its drug-hunter challenge. More

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.